Construction of artificial methemoglobin reduction systems in Hb vesicles

Shinji Takeoka, Tekeru Ohgushi, Hiromi Sakai, Takehiro Kose, Hiroyuki Nishide, Eishun Tsuchida

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The hemoglobin vesicle (HbV) is a red cell substitute encapsulating purified concentrated Hb in a phospholipid vesicle. In order to suppress metHb formation for the long term maintenance of oxygen transporting capability in vivo, thiols (cysteine, Cys; homocysteine, Hcy) were studied as reductants of metHb. Hcy showed a suppressive effect on metHb formation, while Cys adversely accelerates metHb formation at the rate of twice the Hb solution without any reductants. The suppression of Cys-induced metHb formation by the addition of superoxide dismutase (SOD) and catalase indicated that Cys was easily oxidized by oxygen and simultaneously generated a large amount of active oxygens. The rate of metHb formation was influenced by PO2 and pH. Furthermore, the reducing systems (methylene blue (MB), NADH or ascorbic acid) were added to the outer aqueous phase of HbV, and the artificial reduction systems constructed through the bilayer membrane were evaluated.

Original languageEnglish
Pages (from-to)31-41
Number of pages11
JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
Volume25
Issue number1-2
Publication statusPublished - 1997 Jan

Fingerprint

Blood Substitutes
Methemoglobin
Reducing Agents
Hemoglobins
Hemoglobin
Oxygen
Methylene Blue
Homocysteine
Sulfhydryl Compounds
NAD
Catalase
Ascorbic Acid
Superoxide Dismutase
Cysteine
Reactive Oxygen Species
Phospholipids
Ascorbic acid
Membranes
Cells

ASJC Scopus subject areas

  • Biomedical Engineering
  • Hematology
  • Biotechnology
  • Biomaterials

Cite this

Construction of artificial methemoglobin reduction systems in Hb vesicles. / Takeoka, Shinji; Ohgushi, Tekeru; Sakai, Hiromi; Kose, Takehiro; Nishide, Hiroyuki; Tsuchida, Eishun.

In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, Vol. 25, No. 1-2, 01.1997, p. 31-41.

Research output: Contribution to journalArticle

@article{e494568fcc50405da0b8d110bb41d24b,
title = "Construction of artificial methemoglobin reduction systems in Hb vesicles",
abstract = "The hemoglobin vesicle (HbV) is a red cell substitute encapsulating purified concentrated Hb in a phospholipid vesicle. In order to suppress metHb formation for the long term maintenance of oxygen transporting capability in vivo, thiols (cysteine, Cys; homocysteine, Hcy) were studied as reductants of metHb. Hcy showed a suppressive effect on metHb formation, while Cys adversely accelerates metHb formation at the rate of twice the Hb solution without any reductants. The suppression of Cys-induced metHb formation by the addition of superoxide dismutase (SOD) and catalase indicated that Cys was easily oxidized by oxygen and simultaneously generated a large amount of active oxygens. The rate of metHb formation was influenced by PO2 and pH. Furthermore, the reducing systems (methylene blue (MB), NADH or ascorbic acid) were added to the outer aqueous phase of HbV, and the artificial reduction systems constructed through the bilayer membrane were evaluated.",
author = "Shinji Takeoka and Tekeru Ohgushi and Hiromi Sakai and Takehiro Kose and Hiroyuki Nishide and Eishun Tsuchida",
year = "1997",
month = "1",
language = "English",
volume = "25",
pages = "31--41",
journal = "Artificial Cells, Nanomedicine and Biotechnology",
issn = "2169-1401",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Construction of artificial methemoglobin reduction systems in Hb vesicles

AU - Takeoka, Shinji

AU - Ohgushi, Tekeru

AU - Sakai, Hiromi

AU - Kose, Takehiro

AU - Nishide, Hiroyuki

AU - Tsuchida, Eishun

PY - 1997/1

Y1 - 1997/1

N2 - The hemoglobin vesicle (HbV) is a red cell substitute encapsulating purified concentrated Hb in a phospholipid vesicle. In order to suppress metHb formation for the long term maintenance of oxygen transporting capability in vivo, thiols (cysteine, Cys; homocysteine, Hcy) were studied as reductants of metHb. Hcy showed a suppressive effect on metHb formation, while Cys adversely accelerates metHb formation at the rate of twice the Hb solution without any reductants. The suppression of Cys-induced metHb formation by the addition of superoxide dismutase (SOD) and catalase indicated that Cys was easily oxidized by oxygen and simultaneously generated a large amount of active oxygens. The rate of metHb formation was influenced by PO2 and pH. Furthermore, the reducing systems (methylene blue (MB), NADH or ascorbic acid) were added to the outer aqueous phase of HbV, and the artificial reduction systems constructed through the bilayer membrane were evaluated.

AB - The hemoglobin vesicle (HbV) is a red cell substitute encapsulating purified concentrated Hb in a phospholipid vesicle. In order to suppress metHb formation for the long term maintenance of oxygen transporting capability in vivo, thiols (cysteine, Cys; homocysteine, Hcy) were studied as reductants of metHb. Hcy showed a suppressive effect on metHb formation, while Cys adversely accelerates metHb formation at the rate of twice the Hb solution without any reductants. The suppression of Cys-induced metHb formation by the addition of superoxide dismutase (SOD) and catalase indicated that Cys was easily oxidized by oxygen and simultaneously generated a large amount of active oxygens. The rate of metHb formation was influenced by PO2 and pH. Furthermore, the reducing systems (methylene blue (MB), NADH or ascorbic acid) were added to the outer aqueous phase of HbV, and the artificial reduction systems constructed through the bilayer membrane were evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0030945980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030945980&partnerID=8YFLogxK

M3 - Article

C2 - 9083624

AN - SCOPUS:0030945980

VL - 25

SP - 31

EP - 41

JO - Artificial Cells, Nanomedicine and Biotechnology

JF - Artificial Cells, Nanomedicine and Biotechnology

SN - 2169-1401

IS - 1-2

ER -